Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AST2818 in EGFR-TKI–pretreated advanced NSCLC
CTR20170447Phase 2Active
- Sponsor
- Allist Pharmaceuticals
- Start
- Jun 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of furmonertinib in non-small cell lung cancer (NSCLC), sponsored by Allist Pharmaceuticals. Started Jun 2017; status: active.
02
Drugs
furmonertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20170447.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20170447.